Therapeutics

Breaking News

25 Mar 2015 In a phase 1b trial, Aducanumab, a human antibody against aggregated Aβ, cleared amyloid plaques from the brain of people with prodromal Alzheimer’s disease in dose-dependent fashion. Exploratory outcomes suggest the antibody may provide a clinical benefit. Especially in ApoE4 carriers, vascular edema was a common side effect, causing temporary headache and confusion in some cases. This was an interim analysis of an ongoing trial; phase 3 is in preparation. See news

This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at therapeutics@alzforum.org.

Tools

Back to the Top
Search Therapeutics

AD Target / Therapy Types

The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.

Further Reading

News

  1. Biogen Antibody Buoyed by Phase 1 Data and Hungry Investors
  2. More Evidence That Epilepsy Drug Calms Neurons and Boosts Memory
  3. About-Turn—In Mouse Model of Down’s Syndrome, Inhibitory Neurotransmitter Excites
  4. Stop, Hey, What’s That Sound? ... Amyloid Is Going Down?

Webinars

  1. Resolving Controversies on the Path to AD Therapeutics
  2. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD
  3. Of Mice and Men: Bridging the Translational Disconnect in CNS Drug Discovery
  4. Can We (Should We?) Develop “Smart Drugs” to Stave Off Age-Related Memory Loss?

Other Resources

ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.

Patient Resources